Research graph
References from Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
10.1016/s0140-6736(20)30734-0 · 2020 · External reference
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
10.1016/s1470-2045(21)00128-5 · 2021 · External reference
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
10.1056/nejmoa1607751 · 2016 · External reference
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
10.1056/nejmoa1606038 · 2016 · External reference
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
10.1016/s0140-6736(21)00592-4 · 2021 · External reference
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
10.1016/s0140-6736(19)32556-5 · 2019 · External reference
Multiple myeloma
10.1038/s41572-024-00529-7 · 2024 · External reference
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
10.1056/nejmoa1817249 · 2019 · External reference
Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial
10.1200/jco.22.00940 · 2023 · External reference
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
10.1182/blood-2016-03-703439 · 2016 · External reference
CD38 Antibodies in multiple myeloma: mechanisms of action and modes of resistance
10.3389/fimmu.2018.02134 · 2018 · External reference
Infusion reactions associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H
2018 · External reference
Chromosome 1q21 abnormalities in multiple myeloma
10.1038/s41408-021-00474-8 · 2021 · External reference
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
10.3324/haematol.2022.280660 · 2022 · External reference
The importance of FISH signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: is it underestimated?
10.1016/j.clml.2022.01.013 · 2022 · External reference
The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
2021 · External reference
Four-year follow-up of the phase 3 Pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM)
2019 · External reference
Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019
10.1097/cm9.0000000000002600 · 2023 · External reference
MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds
10.1182/blood.v126.23.3015.3015 · 2015 · External reference
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
10.1016/s2352-3026(19)30249-2 · 2020 · External reference
Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: updated analysis of LEPUS
10.1016/j.clml.2022.10.007 · 2023 · External reference
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
10.1186/s13045-017-0501-4 · 2017 · External reference
Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: a real-world cohort study in China
10.1002/cam4.7232 · 2024 · External reference
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
10.1016/s2352-3026(20)30070-3 · 2020 · External reference
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
10.1111/bjh.16292 · 2020 · External reference
